In one paragraphTrial report in Gut and liver, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02473406 (Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis), which is not on this map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis
TypeinterventionalSponsorWeiqin LiRan2018 to 2021Enrolled508ConditionsPancreatitis, Acute NecrotizingArmsThymosin Alpha 1, normal saline
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors at 3 institutions in 2 countries.
Xiaofei HuangDepartment of Emergency and Critical Care Medicine, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0009-0001-7780-5865 Wenjian MaoDepartment of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.ORCID 0000-0002-0033-8939 Xingxing HuDepartment of Emergency and Critical Care Medicine, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0000-0001-6385-4845 Fengxia QinDepartment of Emergency and Critical Care Medicine, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0009-0000-7256-1884 Hui ZhaoDepartment of Emergency and Critical Care Medicine, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0009-0004-9181-5308 Aiping ZhangDepartment of Emergency and Critical Care Medicine, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0009-0008-5559-2943 Xinyu WangDepartment of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.ORCID 0009-0004-6603-514X Christian StoppeDepartment of Anesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Würzburg, Würzburg, Germany.ORCID 0000-0002-2028-2039 Dandan ZhouDepartment of Emergency and Critical Care Medicine, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0000-0002-4041-5150 Lu KeDepartment of Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.ORCID 0000-0001-8093-5073 Haibin NiDepartment of Emergency and Critical Care Medicine, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0000-0003-1726-7943 Chinese Acute Pancreatitis Clinical Trials Group (CAPCTG)
Nanjing University of Chinese Medicine · CNNanjing General Hospital of Nanjing Military Command · CNUniversitätsklinikum Würzburg · DE
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Background/Aims: Metabolic syndrome is common in patients with acute pancreatitis and its components have been reported to be associated with infectious complications. In this Methods: All data were obtained from the database for a multicenter randomized clinical trial that evaluated the efficacy of Tα1 in ANP patients. Patients who discontinued the Tα1 treatment prematurely were excluded. The primary outcome was 90-day infected pancreatic necrosis (IPN) after randomization. Three Results: Overall, 502 participants were included in this Conclusions: Among ANP patients with hyperglycemia, immune-enhancing Tα1 treatment was associated with a reduced risk of IPN (ClinicalTrials.gov, Registry number: NCT02473406).
Indexed as
HyperglycemiaHypertriglyceridemiaPancreatitis, Acute NecrotizingThymalfasinAdultAgedFemaleHumansMaleMetabolic SyndromeMiddle AgedPropensity ScoreProportional Hazards ModelsThymosinTreatment OutcomeThymalfasinThymosinAcute necrotizing pancreatitisHyperglycemiaInfectionMetabolic syndromeThymosin alpha1
Identifiers
PMID38356344
PMCPMC11391137
OpenAlexW4391841359
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390